Pat Keegan
@kakeegs3
Followers
395
Following
1K
Media
7
Statuses
105
Husband, Dad, Urologic Oncologist, and occasional Mountain Biker. T/RT mine.
Nashville, TN
Joined May 2020
Today, we announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A which demonstrated promising efficacy, safety and tolerability. These data will be presented later today as Late-Breaking Abstracts at the Society of Urologic Oncology (SUO) 26th
0
1
4
Clinical research is integral to advancing treatment options and improving outcomes for patients. This past year, @MarkTysonMD is THE top provider in Arizona for enrollment in clinical trials, with genitourinary disease representing over 40% of total accruals!
1
6
32
🚨Out now @NatureMedicine🚨 Final results from #CORE2 combining IVe Creto+Nivo in cis-ineligible MIBC pts https://t.co/fD55kG4tRx No DLTs pCR = 42.1% pCR assoc with baseline free E2F activity, TMB Increased T cell infiltration Formation of TLS assoc with pCR @MoffittNews
11
21
80
@MoffittNews Beyond thrilled to present the data from #CORE2, using neoadj IVe Creto + Nivo in cis-ineligible MIBC #SITC24 @NatureMedicine🚨🚨🚨 👉No DLTs 👉42.1% pCR 👉pCR assoc with TMB, E2F activity 👉Global⬆️T-cell infiltration 👉pCR assoc with induction of TLS https://t.co/fD55kG4tRx
4
7
28
#PIVOT-006: A new chapter in #BladderCancer treatment. @MarkTysonMD @MayoClinic joins @UroDocAsh @MDAndersonNews to discuss @cgoncology's advancements in bladder cancer treatment, focusing on the PIVOT study and other trials. #WatchNow on UroToday > https://t.co/NUdP7hqBYU
0
3
10
An expanded access program for cretostimogene grenadenorepvec has been initiated for patients in the US with BCG-unresponsive NMIBC. #blcsm #urology
https://t.co/8WVkV6JtNk
urologytimes.com
Cretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.
0
1
7
Final results of #CORE001 trial out now @NatureMedicine (1/14) 35 pts with BCG-UR CIS treated w/ Creto + pembro 👉12mo CR (per RBB) = 57.1% (ITT) 👉24mo CR = 54% *(Auth Corr) 👉No patient progressed to MIBC 👉No synergistic toxicity @garysteinbergmd
https://t.co/zo8VHxmYol
19
48
147
Today at #ASCO24: In a phase 2 trial evaluating intravesical delivery of an oncolytic adenovirus + anti-PD-1 in patients with BCG unresponsive, non-muscle invasive #BladderCancer, the complete response rate at 12 months was 57.1% @UrogerliMD
2
13
32
👏 We're thrilled to share positive results from our Phase 2 CORE-001 trial on #NationalCancerSurvivorsDay at #ASCO24! Thank you @UrogerliMD for presenting our poster, and to all our dedicated patients & collaborators. See details: @ASCO Poster Board #296 (Abstract #4601)
0
9
21
#ASCO24 CORE-001: Ph 2, single arm study of Creto + Pembro in BCG-UR, NMIBC w/ CIS @UrogerliMD @urotoday @cgoncology ⚡️n=35 ⚡️CR rate 12 mo: 57.1% ⚡️CR rate 24 mo: 54.3% ⚡️CR rate any time: 82.9% ⚡️95.1% of CRs @ 12 mo remain in CR @ 24 mo ⚡️12 mo landmark RFS: 77.3% ⚡️24 mo
0
10
17
Unveiling our CORE-001 trial results tomorrow at #ASCO24 for BCG-unresponsive HR-#NMIBC! Discover insights into safety, efficacy, and patient-reported outcomes. See how we aim to improve the entire spectrum of #bladdercancer care. @UrogerliMD @garysteinbergMD @TBivala1
0
6
16
📄Phase 2 CORE-001 Final Results: Cretostimogene in combination w/pembrolizumab for BCG-unresponsive HR-#NMIBC showed a 54% (19/35) complete response (CR) rate at 24 months. Poster will be presented at #ASCO24 @UrogerliMD @GarySteinbergMD @TBivala1
ir.cgoncology.com
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage...
0
4
20
📄 @CGOncology is excited to share updated BOND-003 study results for BCG-unresponsive #NMIBC presented by @MarkTysonMD at #AUA24. Thank you to the patients & investigators for advancing this research. Join our IR webcast today at 4:30pm ET for details:
ir.cgoncology.com
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today...
0
6
15
Pivotal results from #BOND-003: a phase 3, single-arm Study of Intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive #NMIBC. Presentation by @MarkTysonMD @MayoClinic. #AUA24 coverage by @zklaassen_md > https://t.co/JI6cGxLFSU
@AmerUrological
0
3
3
Please join us tomorrow, May 3rd, in paradigm shifting practice changing trials session at #AUA24. We will be presenting pivotal results of BOND-003, a phase 3 study of cretostimogene grenadenorepvec for BCGu #BladderCancer, at 10:23 am CDT in the Stars at Night Ballroom.
0
6
21
Highly recommend this. Provides context to and vision behind P2 and other innovative changes at AUA this year
GU cancer highlights at the upcoming #AUA24 annual meeting. @urogeek @VUMCurology joins @UroCancerMD to discuss fresh, innovative sessions designed to elevate clinical practice and the the P2 program in this conversation on UroToday > https://t.co/rQvkySiPYr
@AmerUrological
0
2
11
🗓️ Begin your #AUA24 experience tomorrow, May 3rd with @CGOncology! Hear @MarkTysonMD present BOND-003: Phase 3 results of cretostimogene at 10:23 am CDT in the Stars at Night Ballroom, and afterwards meet our Medical Team at booth #100. Come join us! 🤝 https://t.co/cOADzltuj9
0
3
4
The U.S. markets are open! 🛎️👏Late-stage clinical biopharmaceutical company @cgoncology rings in its listing on @NasdaqExchange!
1
7
16
Happy Hanukkah to all who celebrate! May light and joy fill your homes
1
1
0